新型玻璃体腔注射药物治疗视网膜血管性疾病致黄斑水肿的研究进展  

Research progress on novel intravitreal injection medications for the treatment of macular edema associated with retinal vascular diseases

作　　者：马力兴 马华锋[1] 李旭晖 王滨 MA Li-xing;MA Hua-feng;LI Xu-hui;WANG Bin(Department of Ophthalmology,the Second Affiliated Hospital of Chongqing Medical University,Chongqing 400000,China)

机构地区：[1]重庆医科大学附属第二医院眼科,重庆400000

出　　处：《临床药物治疗杂志》2024年第4期11-16,共6页Clinical Medication Journal

摘　　要：黄斑水肿(ME)是多种血管性和炎症性视网膜疾病的主要并发症。尽管多种疾病可能导致ME,但糖尿病视网膜病变和视网膜静脉阻塞是引起ME最常见的原因。血管内皮生长因子(VEGF)水平的升高和炎症是促进ME形成的两个主要致病因素,玻璃体腔注射抗VEGF药物及糖皮质激素已成为ME的主要治疗方式。本文就全球近期获批上市的3种新型药物治疗ME的研究进展进行阐述,以期为临床应用提供参考。Macular edema(ME)is a major complication of various vascular and inflammatory retinal diseases.While multiple conditions can lead to ME,diabetic retinopathy and retinal vein occlusion are the most common underlying causes.Elevated levels of vascular endothelial growth factor(VEGF)and inflammatory factors are two key pathogenic factors promot⁃ing ME formation.Consequently,intravitreal injections of anti-VEGF drugs and corticosteroids have become the primary treat⁃ment modalities for ME.This article discusses the latest progress of three recently approved novel drugs worldwide for the treat⁃ment of ME,aiming to provide reference for clinical application.

关 键 词：黄斑水肿 糖尿病视网膜病变 视网膜静脉阻塞 血管内皮生长因子 糖皮质激素 

分 类 号：R988.1[医药卫生—药品] R774.1[医药卫生—药学]